[February 26, 2015]

Research and Markets: Diabetic Peripheral Neuropathy Therapeutics Pipeline Review 2015 - 5 Companies & 9 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/ggrn2k/diabetic) has announced the addition of the "Diabetic Peripheral Neuropathy - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along wit latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Astellas Pharma Inc.
• BioChemics, Inc.
• Cebix Incorporated
• Pfizer Inc.
• ViroMed Co., Ltd.

Drug Profiles

• Antimunocel
• ASP-8477
• benfotiamine
• CBX-129801
• CNV-2197944
• epalrestat
• PF-05089771
• Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis
• VM-202

For more information visit http://www.researchandmarkets.com/research/ggrn2k/diabetic

[ Back To TMCnet.com's Homepage ]